A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- Sponsors OxThera
- 20 Feb 2018 Planned number of patients changed from 9 to 12.
- 13 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.
- 13 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.